Vaccinex Sees Mixed Signals In Huntington’s Study
Pepinemab Missed Key Endpoints In Phase II Trial
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
